Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial

医学 肝细胞癌 射频消融术 微波消融 烧蚀 慢性肝病 随机对照试验 外科 内科学 胃肠病学 肝硬化
作者
Naïk Vietti Violi,Rafael Durán,Boris Guiu,Jean–Pierre Cercueil,Christophe Aubé,Antonia Digklia,Isabelle Pache,Pierre Deltenre,Jean‐François Knebel,Alban Denys
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:3 (5): 317-325 被引量:298
标识
DOI:10.1016/s2468-1253(18)30029-3
摘要

Background Radiofrequency ablation is the recommended treatment for patients with hepatocellular carcinoma who have lesions smaller than 3 cm and are therefore not candidates for surgery. Microwave ablation is a more recent technique with certain theoretical advantages that have not yet been confirmed clinically. We aimed to compare the efficacy of both techniques in the treatment of hepatocellular carcinoma lesions of 4 cm or smaller. Methods We did a randomised controlled, single-blinded phase 2 trial at four tertiary university centres in France and Switzerland. Patients with chronic liver disease and hepatocellular carcinoma with up to three lesions of 4 cm or smaller who were not eligible for surgery were randomised to receive microwave ablation (experimental group) or radiofrequency ablation (control group). Randomisation was centralised and done by use of a fixed block method (block size 4). Patients were randomly assigned by a co-investigator by use of the sealed opaque envelope method and were masked to the treatment; physicians were not masked to treatment, since the devices used were different. The primary outcome was the proportion of lesions with local tumour progression at 2 years of follow-up. Local tumour progression was defined as the appearance of a new nodule with features typical of hepatocellular carcinoma in the edge of the ablation zone. All analyses were done in the per-protocol population. The study is completed, but patients will continue to be followed up for 5 years. This study is registered with ClinicalTrials.gov, number NCT02859753. Findings Between Nov 15, 2011, and Feb 27, 2015, 152 patients were randomly assigned: 76 patients to receive microwave ablation and 76 patients to receive radiofrequency ablation. For the per-protocol analysis, five patients were excluded from the microwave ablation group as were three patients from the radiofrequency ablation group. Median follow-up was 26 months (IQR 18–29) in the microwave ablation group and 25 months (18–34) in the radiofrequency ablation group. At 2 years, six (6%) of 98 lesions had local tumour progression in the microwave ablation group as did 12 (12%) of 104 in the radiofrequency ablation group (risk ratio 1·62, 95% CI 0·66–3·94; p=0·27). Complications were infrequent, with only two grade 4 complications (two events of arterial bleeding requiring embolisation, both in the microwave ablation group) and three grade 3 complications (pneumothorax; lesion of the umbilical vein; and intrahepatic segmental necrosis, all in the radiofrequency ablation group). No treatment-related deaths were reported. Interpretation Although we did not find that microwave ablation was more effective than radiofrequency ablation for treatment of hepatocellular carcinoma lesions of 4 cm or smaller, our results show that the proportion of lesions with local tumour progression at 2 years of follow-up was low with both tested percutaneous methods. Funding Microsulis (AngioDynamics).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tqun完成签到,获得积分10
刚刚
you完成签到 ,获得积分10
1秒前
lfy完成签到,获得积分10
1秒前
小毛竹完成签到 ,获得积分10
5秒前
DW的应助被WinStar采纳,获得10
5秒前
智文完成签到 ,获得积分10
7秒前
8秒前
从容棉花糖完成签到,获得积分10
9秒前
Akim的应助被俏皮诺言采纳,获得10
11秒前
junjun2011完成签到 ,获得积分10
11秒前
烟花弥漫完成签到 ,获得积分10
13秒前
明朗完成签到 ,获得积分0
14秒前
about发布了新的文献求助10
14秒前
默默白桃完成签到 ,获得积分10
16秒前
我爱自由民权完成签到,获得积分10
18秒前
阳光雅蕊完成签到,获得积分10
18秒前
hugefrog完成签到,获得积分10
20秒前
wxf666完成签到 ,获得积分10
20秒前
HelloBOB完成签到 ,获得积分10
22秒前
PORCO完成签到,获得积分10
27秒前
英勇雅琴完成签到 ,获得积分10
27秒前
dingo完成签到,获得积分10
30秒前
阿南完成签到 ,获得积分0
31秒前
朴素傲松完成签到,获得积分10
31秒前
追寻微笑完成签到 ,获得积分10
32秒前
taotao完成签到 ,获得积分10
32秒前
zilicai的应助被十二采纳,获得20
32秒前
duktig完成签到 ,获得积分10
33秒前
hooqueen完成签到 ,获得积分10
33秒前
about完成签到,获得积分10
34秒前
韩寒123完成签到,获得积分10
35秒前
特特特特特完成签到,获得积分10
37秒前
bobinson完成签到,获得积分10
37秒前
乐观的星月完成签到 ,获得积分0
41秒前
Hello的应助被liugm采纳,获得10
43秒前
小菀儿完成签到 ,获得积分10
44秒前
Royzeng完成签到 ,获得积分10
48秒前
止咳宝完成签到,获得积分10
48秒前
科研通AI6.3的应助被单身的紊采纳,获得10
50秒前
JonyJie完成签到,获得积分10
50秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190389
求助须知:如何正确求助?哪些是违规求助? 9577468
关于积分的说明 21852623
捐赠科研通 7789041
什么是DOI,文献DOI怎么找? 3436369
关于科研通互助平台的介绍 2560180
邀请新用户注册赠送积分活动 2482995